Print

MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Successful Conclusion of Safety Study in Asthmatic Patients for MDT-637 and Presentation of Overall Phase 1 Results at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium  
9/28/2012 10:41:31 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx, Inc., announced today the completion of its third and final Phase 1 clinical study for MDT-637 with its novel inhaled antiviral fusion inhibitor, MDT-637, for the treatment of RSV infection. MicroDose will present the data from all three clinical studies at the 8th Annual International Respiratory Syncytial Virus Symposium taking place from Sept. 27-30 in Santa Fe, NM. Successful completion of the previous two Phase 1 studies (Study MDT-637-CP-101 and MDT-637-CP-102) was announced on April 24, 2012.
//-->